Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of MMI-0100 oligopeptide compound in preparation of medicine for treating cholestatic liver diseases

A technology for treating cholestasis and a drug, which is applied in the application field of MMI-0100 short peptide compound in the preparation of a drug for treating cholestatic liver disease, can solve problems such as obeticholic acid hepatotoxicity, and achieve the relief of the degree of bile duct hyperplasia and the expression of mRNA. The effect of reducing levels and reducing fibrotic lesions

Active Publication Date: 2021-12-03
XUZHOU MEDICAL UNIV
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, obeticholic acid has certain hepatotoxicity, and UDCA is only effective for some patients

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of MMI-0100 oligopeptide compound in preparation of medicine for treating cholestatic liver diseases
  • Application of MMI-0100 oligopeptide compound in preparation of medicine for treating cholestatic liver diseases
  • Application of MMI-0100 oligopeptide compound in preparation of medicine for treating cholestatic liver diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0023] The histopathological changes of the liver

[0024] 1. Operation

[0025] Fifteen Balb / c mice were randomly divided into control group, model group (DDC) and treatment group (DDC+MMI-0100), with 5 mice in each group. Except for the control group, two groups of mice in the model group and the treatment group were fed 0.1% DDC irradiated feed to establish a cholestatic model. After 1w of DDC feeding, the mice in the treatment group were treated with MMI-0100 intraperitoneally every day. Mice were injected with a dose of 500ug / Kg, continuously injected for 1w, and given a normal diet at the same time. On the last day of drug injection, the mice were sacrificed by cervical dislocation and livers were collected.

[0026] Liver pathological detection: The intact mouse liver was isolated at low temperature, and the liver lesions of the mouse were observed with the naked eye. The tissue of about 5mm×5mm×2mm was taken, fixed in 10% paraformaldehyde for 24h, dehydrated in alcoh...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of an MMI-0100 oligopeptide compound in preparation of a medicine for treating cholestatic liver diseases. The amino acid sequence of the MMI-0100 oligopeptide compound is as follows: YARAAARQARAKALARQLGVAA. After MMI-0100 drug treatment, the fibrosis lesion of the mouse liver is relieved, the infiltration of inflammatory cells is reduced, meanwhile, the hyperplasia degree of the bile duct is relieved, the mRNA expression level of the liver fibrosis gene alpha-SMA is reduced, and the results show that the MMI-0100 has a good treatment effect on the cholestatic liver injury.

Description

technical field [0001] The invention relates to the application of MMI-0100 short peptide compounds in the preparation of drugs for the treatment of cholestatic liver disease, and belongs to the technical field of new uses of MMI-0100 short peptide compounds as drugs. Background technique [0002] Cholestasis is a disorder in the formation and / or flow of bile resulting in disturbance of bile flow and is one of the common complications of liver disease. There are many factors that cause bile flow disorder. Any factor that can cause damage to hepatic bile duct cells and biliary system obstruction can lead to cholestasis. The common factors are parasites, viruses, bacterial infections, autoimmunity, drugs or poisons, Alcohol, stones and genetic metabolism, etc., the common clinical cholestatic diseases mainly include primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC) and cholestasis caused by various types of viral hepatitis . In most cases, cholestasis i...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/16A61P1/16
CPCA61K38/16A61P1/16
Inventor 张蓓蓓张波颜超郑葵阳李静徐娜刘继鑫谈仁秀黄芝月
Owner XUZHOU MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com